del(8p)及TNFRSF10B缺失与慢性淋巴细胞白血病不良预后及氟达拉滨耐药相关
该研究在慢性淋巴细胞白血病(CLL)中刻画了罕见染色体异常del(8p),将迄今最大del(8p) CLL队列(n=57)与非del(8p)队列(n=155)比较,发现del(8p)与不良预后、较短至首次治疗时间、较差总生存及较高Richter转化风险显著相关。在氟达拉滨为基础方案治疗的患者中,del(8p)病例(包括IGHV突变者)的无下次治疗生存和总生存更短。91%的del(8p) CLL丢失一个TNFRSF10B基因拷贝,TNFRSF10B呈单倍剂量不足并参与氟达拉滨诱导细胞死亡的调控,del(8p)消除了氟达拉滨与TRAIL诱导凋亡的协同作用。作者建议在启动氟达拉滨为基础治疗前对适合的CLL患者(即IGHV突变且无TP53破坏)进行del(8p)筛查。
要点
- del(8p)与CLL不良预后、较短至首次治疗时间、较差总生存及较高Richter转化风险显著相关。
- 氟达拉滨为基础治疗者中,del(8p)病例(含IGHV突变者)无下次治疗生存和总生存更短。
- 91%的del(8p) CLL丢失一个TNFRSF10B拷贝,TNFRSF10B单倍剂量不足参与氟达拉滨诱导细胞死亡调控。
核心结论
- del(8p)是CLL的预后标志物,与不良预后及氟达拉滨耐药相关。
- 作者建议在启动氟达拉滨为基础治疗前对适合的CLL患者(即IGHV突变且无TP53破坏)进行del(8p)筛查。
研究设计与样本
- 研究比较迄今最大del(8p) CLL队列(n=57)与非del(8p)队列(n=155)。
- 采用原代细胞实验及CRISPR编辑的TNFRSF10B敲除CLL细胞系进行机制验证。
主要发现
- del(8p)与不良预后、较短至首次治疗时间、较差总生存及较高Richter转化风险显著相关。
- 氟达拉滨为基础方案治疗者中,del(8p)病例(包括IGHV突变者)的无下次治疗生存和总生存更短。
- 91%的del(8p) CLL丢失一个TNFRSF10B基因拷贝,TNFRSF10B呈单倍剂量不足。
- TNFRSF10B参与氟达拉滨诱导细胞死亡的调控,del(8p)消除了氟达拉滨与TRAIL诱导凋亡的协同作用。
关键数值与推荐
- del(8p) CLL队列n=57,非del(8p)队列n=155。
- 91%的del(8p) CLL丢失一个TNFRSF10B基因拷贝。
临床怎么用
- 作者建议在启动氟达拉滨为基础治疗前对适合的CLL患者(即IGHV突变且无TP53破坏)进行del(8p)筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, the prognosis of which varies according to the cytogenetic group. We characterized a rare chromosomal abnormality (del(8p), deletion of the short arm of chromosome 8) in the context of CLL. By comparing the largest cohort of del(8p) CLL to date (n = 57) with a non-del(8p) cohort (n = 155), del(8p) was significantly associated with a poor prognosis, a shorter time to first treatment, worse overall survival (OS), and a higher risk of Richter transformation. For patients treated with fludarabine-based regimens, the next-treatment-free survival and the OS were shorter in del(8p) cases (including those with mutated IGHV). One copy of the TNFRSF10B gene (coding a pro-apoptotic receptor activated by TRAIL) was lost in 91% of del(8p) CLL. TNFRSF10B was haploinsufficient in del(8p) CLL, and was involved in the modulation of fludarabine-induced cell death - as confirmed by our experiments in primary cells and in CRISPR-edited TNFRSF10B knock-out CLL cell lines. Lastly, del(8p) abrogated the synergy between fludarabine and TRAIL-induced apoptosis. Our results highlight del(8p)'s value as a prognostic marker and suggest that fit CLL patients (i.e. with mutated IGHV and no TP53 disruption) should be screened for del(8p) before the initiation of fludarabine-based treatment.
引用
- Jondreville L, Dehgane L, Doualle C, et al. del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia. Leukemia. 2023. PMID: 37752286. doi:10.1038/s41375-023-02035-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。